Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OVRAL-28 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: suppresses gonadotropin release via estrogen and progestin, inhibiting ovulation, thickening cervical mucus, and altering endometrial lining.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females aged ≥15 years who have no known contraindications and have achieved menarche
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (norgestrel 0.3 mg, ethinyl estradiol 0.03 mg) orally once daily for 21 consecutive days, followed by 7 days of placebo.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Ethinyl estradiol: terminal half-life 13-27 hours (mean ~17 hours); norgestrel: terminal half-life 11-45 hours (mean ~24 hours). Clinical context: steady-state reached within 5-7 days; accumulation minimal with daily dosing.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol: primarily hepatic via CYP3A4, undergoes first-pass metabolism; norgestrel: hepatic reduction and conjugation, partially via CYP3A4.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: ~40% as metabolites; fecal: ~60% via biliary excretion, primarily as glucuronide and sulfate conjugates.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinyl estradiol: 97-98% bound, primarily to albumin; norgestrel: 93-95% bound, primarily to sex hormone-binding globulin (SHBG) and albumin.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinyl estradiol: 2.5-4.0 L/kg; norgestrel: 2.0-3.5 L/kg. High Vd indicates extensive tissue distribution and binding.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: ethinyl estradiol ~40-50% (due to first-pass metabolism); norgestrel ~60-70% (variable due to presystemic metabolism).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dosage adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min); use with caution due to potential fluid retention.
No data available for fictional drug ALYACEN 777.
Contraindicated in acute hepatitis, hepatic adenomas, or severe cirrhosis (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), consider alternative therapy; if used, monitor liver function closely and reduce dose if tolerated.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (one tablet daily).
No data available for fictional drug ALYACEN 777.
Not indicated for use after menopause. No specific dosing adjustments provided for elderly patients; consider increased risk of thromboembolic events and cardiovascular disease.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events. Combination oral contraceptives are contraindicated in women over 35 who smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thrombotic disorders (venous thromboembolism, stroke, MI),Elevated blood pressure,Gallbladder disease,Hepatic neoplasia,Glucose intolerance,Retinal thrombosis,Depression
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Current or history of thrombotic disorders,Known or suspected breast carcinoma,Undiagnosed abnormal genital bleeding,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions known; however, grapefruit juice may increase ethinyl estradiol exposure. High-fat meals may slightly reduce absorption but not clinically significant. Advise consistent intake with food to minimize gastrointestinal upset.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Pregnancy category X. First trimester: risk of congenital malformations (neural tube defects, cardiovascular anomalies) and spontaneous abortion. Second and third trimesters: associated with fetal adrenal suppression, hepatic impairment, and potential for masculinization of female genitalia.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Contraindicated during breastfeeding. Estrogens and progestins are excreted in human milk in low concentrations (M/P ratio not established). Potential for adverse effects on the infant including jaundice and breast enlargement.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately upon pregnancy confirmation.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Ovral-28 is a combination oral contraceptive containing norgestrel and ethinyl estradiol. It is dosed as 28-day regimen with 21 active pills and 7 placebo. Patients should be counseled about the risk of thromboembolism, especially if over 35 years old and smoking. Efficacy may be reduced with concurrent use of certain anticonvulsants (e.g., phenytoin, carbamazepine) and antibiotics (e.g., rifampin). Instruct patients to take at the same time daily to maintain consistent serum levels. Missed doses require backup contraception; refer to package insert for missed pill algorithm.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time, preferably with a meal to reduce nausea.,Do not skip pills; if a pill is missed, follow the instructions in the patient information leaflet and use backup contraception as directed.,Smoking increases the risk of serious cardiovascular side effects, especially in women over 35. Avoid smoking while on this medication.,Use backup contraception (like condoms) when starting the pill and if you miss pills or take certain other medications.,Common side effects include nausea, headache, breast tenderness, and breakthrough bleeding, which often improve after 2-3 months.,Seek medical attention immediately if you experience symptoms of blood clots: sudden chest pain, shortness of breath, leg pain/swelling, or sudden severe headache.,This medication does not protect against HIV or other sexually transmitted infections.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OVRAL-28 vs ALYACEN 777, answered by our medical review team.
OVRAL-28 is a Oral Contraceptive that works by Combination oral contraceptive: suppresses gonadotropin release via estrogen and progestin, inhibiting ovulation, thickening cervical mucus, and altering endometrial lining.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OVRAL-28 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OVRAL-28 is: One tablet (norgestrel 0.3 mg, ethinyl estradiol 0.03 mg) orally once daily for 21 consecutive days, followed by 7 days of placebo.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OVRAL-28 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OVRAL-28 is classified as Category C. Pregnancy category X. First trimester: risk of congenital malformations (neural tube defects, cardiovascular anomalies) and spontaneous abortion. Second and third trimesters: assoc. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.